Current Pharmaceutical Analysis Advances to Q2 with 2025 Impact Factor of 3.6
Published 10 July, 2026
Following the release of the 2025 Journal Citation Reports on June 17, 2026, Current Pharmaceutical Analysis (CPA) has achieved a significant milestone, with its Impact Factor rising to 3.6. This accomplishment reflects a marked enhancement in the journal's scholarly impact and international recognition within the pharmaceutical sciences.
In the Pharmacology & Pharmacy category, CPA now ranks 128th out of 356 journals, securing a Q2 position. This upward trajectory places the journal firmly within the upper-middle tier of the field, underscoring the growing visibility and citation impact of the research it publishes. The elevation to Q2 status attests to the journal’s strengthening academic reputation and its increasing relevance to the global pharmacology community.
The editorial team extends its deepest appreciation to the dedicated board members, rigorous reviewers, insightful authors, and engaged readers whose collective efforts have been instrumental in driving this progress. Their unwavering commitment to quality and scholarly excellence has been fundamental to CPA's continued advancement. Looking ahead, Current Pharmaceutical Analysis remains steadfast in its mission to advance the frontier of pharmaceutical analysis.